Esaote’s E-Scan gets final FDA nod

Article

The Food and Drug Administration last month cleared—for the second time—Italian biomedical firm Esaote’s E-Scan MRI system. Although the agency originally approved the system last summer, the FDA requested another application when

The Food and Drug Administration last month cleared—for the second time—Italian biomedical firm Esaote’s E-Scan MRI system. Although the agency originally approved the system last summer, the FDA requested another application when Genoa-based Esaote made what the FDA considered significant changes in the unit’s gradient system during the final development stage.

E-Scan is an open-style MRI scanner dedicated to orthopedic studies, and includes a swiveling patient table between 0.2-tesla permanent magnets. Esaote supplies the unit to U.S. marketing partners Lunar of Madison, WI, and Siemens Medical Systems of Iselin, NJ (SCAN Special Report 1/99).

The agency’s request for a second 510(k) application for E-Scan came as a surprise, according to Lunar, and delayed the product’s launch. Esaote had planned to ship the units in the first quarter of 1999, but since the second 510(k) application was submitted on March 23 and cleared on May 27, the company’s commercialization calendar was interrupted. Although a Lunar spokesperson downplayed the effect of the delay, Lunar’s third quarter fiscal 1999 (end-March) results took a hit when the company couldn’t recognize revenue for $2.7 million in E-Scan orders (SCAN 4/28/99).

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.